Beam Therapeutics Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Beam Therapeutics Inc. (BEAM) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $9.67 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2025-02-25
- Beam Therapeutics Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $9.67M, a 1.57% increase from fiscal 2023.
- Beam Therapeutics Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $9.52M, a 12.92% increase from fiscal 2022.
- Beam Therapeutics Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $8.43M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|
| 2024-12-31 | $9.67M 10-K · filed 2025-02-25 |
| 2023-12-31 | $9.52M 10-K · filed 2025-02-25 |
| 2022-12-31 | $8.43M 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |